

# *Journal of Health Disparities Research and Practice*

---

Volume 12, Issue 4

2018

Article 51

2019 STEP-UP SPECIAL ISSUE

---

## Effects of Epac1 on Diabetic Retinal Inflammation

Claire Hawthorne\*

Jena Steinle, PhD<sup>†</sup>

Youde Jiang, MS<sup>‡</sup>

Li Liu, PhD\*\*

\*

<sup>†</sup>Wayne State University School of Medicine

<sup>‡</sup>Wayne State University School of Medicine

\*\*Wayne State University School of Medicine

Copyright ©2018 by the authors. *Journal of Health Disparities Research and Practice* is produced by The Berkeley Electronic Press (bepress). <https://digitalscholarship.unlv.edu/jhdrp>

# Effects of Epac1 on Diabetic Retinal Inflammation\*

Claire Hawthorne; Jena Steinle, PhD; Youde Jiang, MS; and Li Liu, PhD

## Abstract

An ever-growing body of research suggests that inflammation is one of the primary causes of diabetic retinopathy, as the inflammation can lead to insulin resistance. Beta-adrenergic receptor agonists can reduce the inflammation in human retinal endothelial cells (HRECs), but are not a viable treatment due to systemic effects. Epac1 lies downstream of beta-adrenergic receptor signaling, and it may have the capability to reduce inflammation by acting as an alternative pathway for beta-adrenergic receptor agonists to block inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1B). We hypothesized that the Epac1 agonist will decrease cytokine levels, leading to improved insulin signal transduction in the retina.

HRECs were grown in normal (5mM) or high glucose (25mM). Some cells were not treated with the Epac1 agonist and serve as controls. Western blotting was done using primary antibodies for total and phosphorylated insulin receptor substrate-1 (IRS-1), insulin receptor (IR) and Akt, as well as beta actin as a control for loading. Anti-Rabbit IgG/HRP was used for secondary antibodies. ELISA analyses were done for protein levels of TNF-alpha and IL-1B. We are not done with data analyses, but we expect to find that Epac1 will increase insulin receptor and Akt phosphorylation, while reducing TNF-alpha and IL-1B levels.

**KEYWORDS:** Diabetic retinopathy; Epac1; inflammation; TNF-alpha; Western blot

---

\*The STEP-UP HS program is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health Grant: 2R25DK078382-12.



**Journal of Health Disparities Research and Practice**  
**Volume 12, STEP-UP Special Issue, Summer 2019, pp. 72**  
© 2011 Center for Health Disparities Research  
School of Public Health  
University of Nevada, Las Vegas

## **Effects of Epac1 on Diabetic Retinal Inflammation**

Claire Hawthorne

Jena Steinle, PhD, Wayne State University School of Medicine

Youde Jiang, MS, Wayne State University School of Medicine

Li Liu, PhD, Wayne State University School of Medicine

**Coordinating Center:** Stanford University

### **ABSTRACT**

An ever-growing body of research suggests that inflammation is one of the primary causes of diabetic retinopathy, as the inflammation can lead to insulin resistance. Beta-adrenergic receptor agonists can reduce the inflammation in human retinal endothelial cells (HRECs), but are not a viable treatment due to systemic effects. Epac1 lies downstream of beta-adrenergic receptor signaling, and it may have the capability to reduce inflammation by acting as an alternative pathway for beta-adrenergic receptor agonists to block inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1B). We hypothesized that the Epac1 agonist will decrease cytokine levels, leading to improved insulin signal transduction in the retina.

HRECs were grown in normal (5mM) or high glucose (25mM). Some cells were not treated with the Epac1 agonist and serve as controls. Western blotting was done using primary antibodies for total and phosphorylated insulin receptor substrate-1 (IRS-1), insulin receptor (IR) and Akt, as well as beta actin as a control for loading. Anti-Rabbit IgG/HRP was used for secondary antibodies. ELISA analyses were done for protein levels of TNF-alpha and IL-1B. We are not done with data analyses, but we expect to find that Epac1 will increase insulin receptor and Akt phosphorylation, while reducing TNF-alpha and IL-1B levels.

**Keywords:** Diabetic retinopathy, Epac1, inflammation, TNF-alpha, Western blot

### **ACKNOWLEDGEMENTS**

The STEP-UP HS program is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health Grant: 2R25DK078382-12.

Journal of Health Disparities Research and Practice Volume 12, STEP-UP Special Issue,  
Summer 2019

<http://digitalscholarship.unlv.edu/jhdrp/>

Follow on Facebook: Health.Disparities.Journal

Follow on Twitter: @jhdrp